Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,19 MB, PDF-dokument
To explore the efficacy and safety of semaglutide 2.4 mg in people with overweight/obesity who were also being treated with antidepressants (ADs).
Methods
Across the Semaglutide Treatment Effect for People with obesity (STEP) 1–3 and 5 trials, adults with overweight/obesity and type 2 diabetes (STEP 2 only) were enrolled. People with severe major depressive disorder within 2 years prior to screening or with a patient health questionnaire-9 score ≥15 at screening were excluded. Participants were categorized into subgroups according to baseline AD status (on/off ADs) in this post hoc exploratory analysis of the STEP trials.
Results
Of 3683 participants randomized, 539 were on ADs at baseline. Mean body weight change from baseline to week 68 was greater for semaglutide versus placebo, regardless of baseline AD use. In STEP 1, for participants on ADs at baseline, mean change from baseline was −15.7% with semaglutide versus −0.2% with placebo and −14.7% versus −2.8% for those not on ADs at baseline. Similar patterns were seen in STEP 2, 3, and 5. The prevalence of adverse events (AEs) was generally similar between semaglutide and placebo in participants on ADs at baseline.
Conclusions
In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Obesity |
| Vol/bind | 32 |
| Udgave nummer | 2 |
| Sider (fra-til) | 273-280 |
| Antal sider | 8 |
| ISSN | 1930-7381 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
The authors thank the trial participants, the investigators, and the trial site staff who conducted the trials. Medical writing assistance was provided by Sarah Stowell, a contract writer working on behalf of Apollo, OPEN Health Communications, and Casey McKeown RVN, FdSc, of Apollo, OPEN Health Communications, and funded by Novo Nordisk, in accordance with Good Publication Practice 2022 (GPP 2022) guidelines ( https://www.ismpp.org/gpp-2022 ).
Funding Information:
Robert F. Kushner has participated in advisory boards for Novo Nordisk and was an investigator for the STEP 1 and STEP 2 trials. Thomas Wadden serves on advisory boards for Novo Nordisk and WW, and he has received research funds (on behalf of the University of Pennsylvania) from Novo Nordisk. Ofir Frenkel and Bryan Goldman are employees and shareholders of Novo Nordisk. Maria Overvad is an employee of Novo Nordisk. Anders Fink‐Jensen has received an unrestricted research grant from Novo Nordisk. Barbara McGowan reports receiving educational fees from Merck, lecture fees from Janssen Biotech, advisory board fees from Johnson & Johnson Health Care Systems and Lilly, grant support, paid to Guys and St. Thomas' Hospital, consulting fees, and educational fees from Novo Nordisk, and owning stock in Reset Health Clinics.
Publisher Copyright:
© 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
ID: 381023940